Loading…
Levity Inc. was cited for misbranding compounded semaglutide and liraglutide products sold through its website, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drugs when it was not, and made misleading claims suggesting the products were FDA-approved or equivalent to branded drugs like Ozempic®, Wegovy®, and Saxenda®, despite compounded drugs lacking FDA approval. These false and misleading statements in advertising and labeling rendered the products misbranded and introduced them into interstate commerce in violation of the FDCA.